BioMotiv And Biogen Form Strategic Partnership In Neuroscience

CLEVELAND, OH--(Marketwired - September 21, 2015) - BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development centered at University Hospitals in Cleveland, Ohio, announced today that it has entered into a strategic partnership with Biogen. This discovery collaboration will leverage the strengths of both organizations to identify pioneering neuroscience discoveries and advance them into medicines.

Biogen has committed to invest $15 million in BioMotiv over five years, providing Biogen with exclusive rights relating to neuroscience programs sourced and developed by BioMotiv.

“Biogen is the leading company for developing novel neuroscience therapeutics,” said Baiju R. Shah, Chief Executive Officer of BioMotiv. “This partnership completes a platform to advance novel medicines that address some of the most complex medical challenges.”

BioMotiv is the for-profit component of The Harrington Project for Discovery & Development. Launched in 2012, The Harrington Project is a $250 million international initiative with an aim of identifying, funding, and rapidly advancing the development of medical breakthroughs from innovative physician-scientists throughout the US and UK. In pursuing its mission, The Harrington Project also works in partnership with disease foundations such as the Alzheimer’s Drug Discovery Foundation. It is unique in focusing on physician-scientists and providing comprehensive expert resources and funding to advance these discoveries into innovative, new medicines.

“Biogen is committed to working with the world’s leading clinicians and scientists to accelerate the discovery of novel neuroscience medicines,” said Spyros Artavanis-Tsakonas, Senior Vice President and Chief Scientific Officer at Biogen. “Partnering with BioMotiv allows us to source programs through the innovative model of The Harrington Project, and to develop breakthrough therapies that have the potential to provide benefits for patients.”

About BioMotiv
BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $250 million national initiative for advancing medicine centered at University Hospitals in Cleveland. The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations. The company leverages an experienced team and advisory board to select, fund, and actively manage and advance a portfolio of programs. Learn more at www.biomotiv.com.